SUMMARY TABLE FOR SARS CASE CLASSIFICATION

SARS	Epi Criteria	Clinical Criteria for Degree of Illness			
Activity	\$11 L1	Early: Two or more of the following: Fever (may be subjective), chills, rigors, myalgia, headache, diarrhea, sore throat, rhinorrhea	Mild- Moderate: Temperature > 100.4°F AND at least one of the following: Cough, shortness of breath, difficulty breathing, hypoxia	Severe: Temperature > 100.4°F AND At least one symptom of mild-moderate respiratory illness AND at least one of the following: X-ray evidence of pneumonia, respiratory distress syndrome (RDS), autopsy findings consistent with RDS without identifiable cause	
No activity worldwide	*Healthcare worker <u>OR</u> *Within 10 days prior to symptom onset either: (a) Travel to China, Hong Kong or Taiwan (b) Contact with ill persons who traveled to these areas <u>OR</u> *Close contact with persons with unexplained pneumonia			For hospitalized cases only Report Under Investigation – 1 (RUI-1)	
Activity anywhere in the world	Possible Exposure: Within 10 days prior to symptom onset: * Exposure to location with known SARS transmission OR *Close contact with probable SARS case		RUI - 2	RUI - 3	
	Probable Exposure: Within 10 days prior to symptom onset: *Close contact with either a confirmed SARS case OR with person with respiratory illness who is epi- linked to a confirmed SARS case	RUI - 4	RUI - 4	Probable SARS Co-V case	

Reports with Definitive Laboratory Testing

Initial Reporting	Laboratory Testing Results			
Category	Negative*	Positive**	Not Done	
RUI 1-4	Excluded	Confirmed SARS-CoV	Indeterminate	
KOTT 4		case	maeternmate	
Probable SARS-CoV	Excluded	Confirmed SARS-CoV	Probable SARS-CoV	
Disease		case	case	

- * Antibody to SARS-CoV is undetectable in a serum specimen obtained > 28 days after onset of illness
- ** Detection of serum antibody to SARS-CoV by a validated test (e.g., enzymelinked immunosorbent assay [ELISA]

Ot

Isolation in cell culture of SARS-CoV from a clinical specimen and PCR confirmation using a test validated by CDC

Or

Detection of SARS-CoV RNA by a reverse transcription-polymerase chain reaction (RT-PCR) test validated by CDC from:

 One specimen tested on two occasions using the original clinical specimen on each occasion

Or

 Two specimens from different sources (e.g., nasopharyngeal and stool)

Or

■ Two specimens collected from the same source on two different days (e.g., 2 nasopharyngeal aspirates)